Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-related cortical blindness.

O Merimsky1, P Nisipeanu, A Loewenstein

  • 1Department of Oncology, Tel-Aviv Medical Center, Israel.

Cancer Chemotherapy and Pharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations.

International journal of retina and vitreous·2022
Same author

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.

ESMO open·2021
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Alpha-interferon treatment can cause cortical blindness, a severe vision loss from occipital lobe damage. This rare side effect was observed in a patient with metastatic renal-cell carcinoma, suggesting a toxic reaction to the chemotherapy.

Area of Science:

  • Neuroscience
  • Oncology
  • Ophthalmology

Background:

  • Cortical blindness results from bilateral occipital lobe lesions.
  • It is a rare but severe adverse effect of chemotherapy.
  • Metastatic renal-cell carcinoma treatment involves agents like alpha-interferon.

Observation:

  • A 75-year-old man developed cortical blindness during alpha-interferon therapy.
  • Neurological examination revealed no focal deficits.
  • Repeated brain CT scans showed no structural occipital lobe damage.

Findings:

  • The patient's cortical blindness was diagnosed despite normal CT findings.
  • The temporal link between alpha-interferon treatment and vision loss suggests causality.
  • Metabolic or toxic effects are suspected as the cause of blindness.

Related Experiment Videos

Implications:

  • Alpha-interferon may induce cortical blindness through non-structural mechanisms.
  • This case highlights the importance of considering iatrogenic causes for vision loss in cancer patients.
  • Further research is needed to elucidate the toxicological pathways involved.